profit from every $100 of sales.
$0$100
Kezar Life Sciences
We have no price for Kezar Life Sciences since 11 May 2026. It may have been taken over, merged or renamed, so the figures below are from then.
$7.29+0.00% today
+72.7% since Oct 10, 25
1-year low $4.171-year high $7.45
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Kezar Life Sciences sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$56.0 million of profit last year.
SalesProfit
Kezar Life Sciences vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Kezar Life Sciences | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Kezar Life Sciences's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 7 | 0 | 0 | |
| – | – | – | – | |
| -71 | -105 | -89 | -52 | |
| -66 | -99 | -81 | -54 | |
| -68 | -102 | -84 | -56 | |
| -10.10 | -14.04 | -11.00 | -7.66 | |
| – | – | – | – | |
| – | -1,503.4% | – | – | |
| – | -1,455.3% | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 300 | 221 | 145 | 77 |
| Cash | 40 | 35 | 42 | 72 |
| Total debt | 21 | 19 | 16 | 2 |
| Total liabilities | 30 | 34 | 28 | 7 |
| 270 | 188 | 117 | 70 | |
| 7 | 7 | 7 | 7 | |
| -18.2% | -38.4% | -48.8% | -59.6% | |
| -25.3% | -54.3% | -71.6% | -80.0% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -59 | -82 | -74 | -52 | |
| 2 | 2 | 0 | 0 | |
| -60 | -83 | -74 | -52 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 14 | 18 | 13 | 9 |
Valuation
- –
- –
- –
- 0.8×
- 7.7×
- –
- –
- -155.0%
- -189.2%
- 0.0%
Profitability
- 0.0%
- -1,503.4%
- -1,455.3%
- 0.0%
- -63.1%
- -47.8%
- -58.4%
- -66.5%
- -64.4%
- –
Growth
- –
- –
- +30.2%
- –
- −39.0%
Financial health
- -0.2×
- 0.02
- 2.0%
- -50.0×
- 24.46
- 24.46
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 4%of 952
What analysts expect
- Average price target
- $11.00
- Range
- $5.00 – $21.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 11, 2026 | -0.78 | -0.98 | +20.4% |
| Mar 27, 2026 | -1.99 | -1.31 | −52.0% |
| Nov 12, 2025 | -1.53 | -1.81 | +15.5% |
| Aug 13, 2025 | -1.87 | -2.15 | +13.0% |
| May 13, 2025 | -2.27 | -2.56 | +11.3% |
| Mar 25, 2025 | -2.77 | -2.71 | −2.2% |
| Nov 12, 2024 | -2.78 | -3.03 | +8.3% |
| Aug 13, 2024 | -2.80 | -3.20 | +12.5% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
41No pass
Benjamin Graham
74Pass
Philip Fisher
42No pass
Peter Lynch
10No pass
Joel Greenblatt
0No pass
Charlie Munger
39No pass
Terry Smith
39No pass
Questions about Kezar Life Sciences
Is Kezar Life Sciences a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Kezar Life Sciences AI analysis
What does Kezar Life Sciences do?
Kezar Life Sciences, Inc. is a United States-based clinical-stage biopharmaceutical company focused on identifying and advancing novel small molecule therapies. Its mission is to address significant unmet medical needs in both immune-mediated diseases and various forms of cancer. It is in Biotechnology.
Does Kezar Life Sciences pay a dividend?
No. Kezar Life Sciences does not pay a dividend at the moment.
Is Kezar Life Sciences stock halal?
No. Kezar Life Sciences does not pass our halal screen: its cash and confirmed interest-bearing investments are 134% of its market value, at or above the 33% limit. How we check
Who are Kezar Life Sciences's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Kezar Life Sciences's.
Prices: daily closes to May 11, 2026. Fundamentals: company reports via invest-like data.